A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

February 23, 2021

Study Completion Date

August 19, 2021

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Vamorolone

Oral administration of 2.0 mg/kg/day for the duration of the study.

DRUG

Prednisone

Oral administration of 0.75 mg/kg/day for 24 weeks.

OTHER

Placebo

Oral administration of placebo daily for 24 weeks.

DRUG

Vamorolone

Oral administration of 6.0 mg/kg/day for the duration of the study.

DRUG

Prednisone

Oral administration of 0.75 mg/kg/day for 24 weeks.

OTHER

Placebo

Oral administration of placebo daily for 24 weeks.

DRUG

Vamorolone

Oral administration of 2.0 mg/kg/day for 20 weeks.

DRUG

Vamorolone

Oral administration of 6.0 mg/kg/day for 20 weeks.

Trial Locations (33)

23219

Children's Hospital of Virginia of Virginia Commonwealth University, Richmond

27710

Duke Children's Hospital, Durham

32827

Nemours Children's Hospital, Orlando

41685

Queen Silvia Children's Hospital, Gothenburg

49202

Schneider Children's Medical Center, Petah Tikvah

55101

Gillette Children's Speciality Health Care, Saint Paul

60611

Ann & Robert H. Lurie Children's Hospital, Chicago

75207

University of Texas Southwestern Medical Center, Dallas

80045

Children's Hospital Colorado, Aurora

90095

University of California Los Angeles, Los Angeles

95616

University of California Davis, Davis

98105

Seattle Children's Hospital, Seattle

Unknown

Royal Children's Hospital, Melbourne

Sydney Children's Hospital, Westmead

Ghent University Hospital, Ghent

University Hospitals Leuven, Leuven

University Hospital Brno, Brno

Charles University, Prague

Agia Sofia Children's Hospital, Athens

Leiden University Medical Center, Leiden

Radboud University, Nijmegen

Sant Joan de Deu Hospital - Barcelona, Spain, Barcelona

Hospital Universitario y Politécnico La Fe, Valencia

Birmingham Heartlands Hospital, Birmingham

Leeds Teaching Hospital Trust, Leeds

Great Ormond Street Hospital, London

AB T3B 6A8

Alberta's Children Hospital, Calgary

V6H 3N1

British Columbia Children's Hospital, Vancouver

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

H4A 3J1

Montreal Children's Hospital, Montreal

G51 4TF

Royal Hospital for Children, Glasgow

L12 2AP

Alder Hey Children's NHS Foundation Trust, Liverpool

NE7 7DN

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors
collaborator

European Union

OTHER

collaborator

Cooperative International Neuromuscular Research Group

NETWORK

collaborator

Newcastle University

OTHER

collaborator

University of Pittsburgh

OTHER

lead

ReveraGen BioPharma, Inc.

INDUSTRY

NCT03439670 - A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter